Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rankning i aktier #17592
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aktiekurs
$8.16
Senast synkroniserad: 2025-06-26
Marknadsvärde
$234.57M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)

Kategori

P/S-tal för Regulus Therapeutics Inc. (RGLS)
P/S-tal per September 2026 TTM: 0.00
Enligt Regulus Therapeutics Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 0.00. I slutet av 2023 hade företaget ett P/S-tal på 0.00.
Historik för P/S-tal för Regulus Therapeutics Inc. från 2010 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 4.72 109.88%
2019 2.25 -98.00%
2018 112.61 -92.50%
2017 1.50K 1,409.28%
2016 99.52 360.84%
2015 21.60 -76.58%
2014 92.22 534.60%
2013 14.53 256.69%
2012 4.07 5,109.59%
2011 0.08 -37.59%
2010 0.13 0.00%
P/S-tal för liknande företag eller konkurrenter
Företag P/S-tal Skillnad i P/S-tal Land
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH